<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">TPX</journal-id>
<journal-id journal-id-type="hwp">sptpx</journal-id>
<journal-id journal-id-type="nlm-ta">Toxicol Pathol</journal-id>
<journal-title>Toxicologic Pathology</journal-title>
<issn pub-type="ppub">0192-6233</issn>
<issn pub-type="epub">1533-1601</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0192623312464309</article-id>
<article-id pub-id-type="publisher-id">10.1177_0192623312464309</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Regular Articles</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Evaluation of Expression Profiles of Hematopoietic Stem Cell, Endothelial Cell, and Myeloid Cell Antigens in Spontaneous and Chemically Induced Hemangiosarcomas and Hemangiomas in Mice</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Kakiuchi-Kiyota</surname>
<given-names>Satoko</given-names>
</name>
<xref ref-type="aff" rid="aff1-0192623312464309">1</xref>
<xref ref-type="aff" rid="aff2-0192623312464309">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Crabbs</surname>
<given-names>Torrie A.</given-names>
</name>
<xref ref-type="aff" rid="aff3-0192623312464309">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Arnold</surname>
<given-names>Lora L.</given-names>
</name>
<xref ref-type="aff" rid="aff1-0192623312464309">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Pennington</surname>
<given-names>Karen L.</given-names>
</name>
<xref ref-type="aff" rid="aff1-0192623312464309">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Cook</surname>
<given-names>Jon C.</given-names>
</name>
<xref ref-type="aff" rid="aff2-0192623312464309">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Malarkey</surname>
<given-names>David E.</given-names>
</name>
<xref ref-type="aff" rid="aff4-0192623312464309">4</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Cohen</surname>
<given-names>Samuel M.</given-names>
</name>
<xref ref-type="aff" rid="aff1-0192623312464309">1</xref>
<xref ref-type="corresp" rid="corresp1-0192623312464309"/>
</contrib>
</contrib-group>
<aff id="aff1-0192623312464309"><label>1</label>Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, Nebraska, USA</aff>
<aff id="aff2-0192623312464309"><label>2</label>Drug Safety Research and Development, Pfizer, Inc.,Groton, Connecticut, USA</aff>
<aff id="aff3-0192623312464309"><label>3</label>Experimental Pathology Laboratories, Inc., Research Triangle Park, North Carolina, USA</aff>
<aff id="aff4-0192623312464309"><label>4</label>Cellular and Molecular Pathology Branch, National Toxicology Program and National Institute of Environmental Health Sciences, Research Triangle Park, North Carolina, USA</aff>
<author-notes>
<corresp id="corresp1-0192623312464309">Samuel M. Cohen, 983135 Nebraska Medical Center, Omaha, Nebraska 68198, USA; e-mail: <email>scohen@unmc.edu</email>.</corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>7</month>
<year>2013</year>
</pub-date>
<volume>41</volume>
<issue>5</issue>
<fpage>709</fpage>
<lpage>721</lpage>
<permissions>
<copyright-statement>© 2012 by The Author(s)</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="society">Society of Toxicologic Pathology</copyright-holder>
</permissions>
<abstract>
<p>It is unclear whether the process of spontaneous and chemically induced hemangiosarcoma and hemangioma formation in mice involves the transformation of differentiated endothelial cells (ECs) or recruitment of multipotential bone marrow–derived hematopoietic stem cells or endothelial progenitor cells (EPCs), which show some degree of endothelial differentiation. In the present study, immunohistochemical staining for hematopoietic stem cell markers (CD45 and CD34), EC markers (vascular endothelial growth factor receptor 2 [VEGFR2], CD31, and factor VIII–related antigen), and a myeloid lineage marker (CD14) was employed to better define the origin of hemangiosarcomas and hemangiomas in mice. Staining was negative for CD45, factor VIII–related antigen, and CD14 and positive for CD34, VEGFR2, and CD31, indicating that mouse hemangiosarcomas and hemangiomas are composed of cells derived from EPCs expressing CD34, VEGFR2, and CD31 but not factor VIII–related antigen. The lack of CD45 expression suggests that mouse vascular tumors may arise from EPCs that are at a stage later than hematopoietic stem cells. Since factor VIII–related antigen expression is known to occur later than CD31 expression in EPCs, our observations may indicate that these tumor cells are arrested at a stage prior to complete differentiation.  In addition, myeloid lineage cells do not appear to contribute to hemangiosarcoma and hemangioma formation in mice. </p>
</abstract>
<kwd-group>
<kwd>mouse</kwd>
<kwd>hemangiosarcomas</kwd>
<kwd>hemangiomas</kwd>
<kwd>hematopoietic stem cells</kwd>
<kwd>endothelial progenitor cells</kwd>
<kwd>immunohistochemistry.</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section1-0192623312464309">
<title>Introduction</title>
<p>Hemangiosarcomas are aggressive malignant tumors characterized by the presence of irregular vasoformative structures consisting of multilayered or solid clusters of endothelial cells (ECs; <xref ref-type="bibr" rid="bibr11-0192623312464309">Hardisty et al. 2007</xref>). The occurrence of hemangiosarcomas is rare in humans, usually with no known cause. The only known causes of hemangiosarcomas in humans are a few rare genetic disorders and exposure to certain genotoxic agents, such as vinyl chloride and thorotrast (<xref ref-type="bibr" rid="bibr3-0192623312464309">Cohen et al. 2009</xref>). Hemangiosarcomas have recently become the focus of considerable attention because a wide range of nongenotoxic chemical agents and pharmaceutical agents, such as peroxisome proliferator–activated receptor (PPAR) agonists, are reported to increase the incidence of hemangiosarcomas, primarily in mice as demonstrated in 2-year carcinogenicity studies (<xref ref-type="bibr" rid="bibr3-0192623312464309">Cohen et al. 2009</xref>).  We have proposed that the sarcomagenic PPARγ agonist, troglitazone, increased EC proliferation, and decreased apoptosis in mice led to an elevation in spontaneous mutations, resulting in hemangiosarcoma formation (<xref ref-type="bibr" rid="bibr19-0192623312464309">Kakiuchi-Kiyota et al. 2009</xref>; <xref ref-type="bibr" rid="bibr20-0192623312464309">Kakiuchi-Kiyota et al. 2011a</xref>, <xref ref-type="bibr" rid="bibr21-0192623312464309">2011b</xref>). </p>
<p>It is not well understood whether hemangiosarcomas originate from differentiated ECs that undergo mutations which endow them with malignant potential or from transformed endothelial progenitor cells (EPCs; <xref ref-type="bibr" rid="bibr25-0192623312464309">Lamerato-Kozicki et al. 2006</xref>). Although the origin of EPCs and the course of differentiation to mature ECs are not well understood, there are numerous studies showing that adult bone marrow and peripheral blood contain EPCs that are capable of differentiating into mature ECs (<xref ref-type="bibr" rid="bibr16-0192623312464309">Hristov and Weber 2004</xref>; <xref ref-type="bibr" rid="bibr34-0192623312464309">Schatteman and Awad 2004</xref>; <xref ref-type="bibr" rid="bibr37-0192623312464309">Urbich and Dimmeler 2004</xref>). It has been proposed that EPCs are derived from bone marrow hematopoietic stem cells. These hematopoietic stem cells have been demonstrated to express hematopoietic stem cell markers, including CD133, CD45, and CD34 (<xref ref-type="bibr" rid="bibr16-0192623312464309">Hristov and Weber 2004</xref>; <xref ref-type="bibr" rid="bibr37-0192623312464309">Urbich and Dimmeler 2004</xref>). Among these markers, CD133 is expressed in more immature stem cells, such as hematopoietic stem cells and/or early EPCs located in the bone marrow or in blood just after migration into the circulation (<xref ref-type="bibr" rid="bibr16-0192623312464309">Hristov and Weber 2004</xref>). Purified CD133-positive cells can differentiate to ECs <italic>in vitro</italic> (<xref ref-type="bibr" rid="bibr8-0192623312464309">Gehling et al. 2000</xref>; <xref ref-type="bibr" rid="bibr22-0192623312464309">Kanayasu-Toyoda et al. 2003</xref>). Expression of CD133 is decreased in late progenitor cells and absent in mature ECs (<xref ref-type="bibr" rid="bibr9-0192623312464309">Handgretinger et al. 2003</xref>; <xref ref-type="bibr" rid="bibr16-0192623312464309">Hristov and Weber 2004</xref>). In contrast, expression of CD34 is not restricted to hematopoietic stem cells or early EPCs but is also present in late EPCs and mature ECs at lower levels (<xref ref-type="bibr" rid="bibr16-0192623312464309">Hristov and Weber 2004</xref>; <xref ref-type="bibr" rid="bibr37-0192623312464309">Urbich and Dimmeler 2004</xref>). CD45 is expressed in hematopoietic stem cells and in both lymphoid and myeloid cell lineages from progenitor to mature cells (<xref ref-type="bibr" rid="bibr13-0192623312464309">Hermiston, Xu, and Weiss 2003</xref>). The course of CD45 expression from hematopoietic stem cells to EPCs is unclear. </p>
<p>Early EPCs located in the bone marrow or in blood just after migration into the circulation begin to express the EC marker, vascular endothelial growth factor receptor 2 (VEGFR2), in addition to CD133 and CD34 (<xref ref-type="bibr" rid="bibr16-0192623312464309">Hristov and Weber 2004</xref>; <xref ref-type="bibr" rid="bibr34-0192623312464309">Schatteman and Awad 2004</xref>; <xref ref-type="bibr" rid="bibr37-0192623312464309">Urbich and Dimmeler 2004</xref>). Recently, it was reported that the frequency of circulating cells expressing CD133, CD34, and VEGFR2 collected from human peripheral blood was extremely low (approximately 84 per 10<sup>6</sup> mononuclear cells) and that &gt;99% of these cells also expressed CD45 (<xref ref-type="bibr" rid="bibr2-0192623312464309">Case et al. 2007</xref>). During differentiation from EPCs to mature ECs, the circulating EPCs lose CD133 expression and begin to express mature EC markers, such as CD31 and factor VIII–related antigen (or von Willebrand factor [vWF]), which is one of three components of factor VIII (<xref ref-type="bibr" rid="bibr10-0192623312464309">Harach, Jasani, and Williams 1983</xref>; <xref ref-type="bibr" rid="bibr16-0192623312464309">Hristov and Weber 2004</xref>; <xref ref-type="bibr" rid="bibr34-0192623312464309">Schatteman and Awad 2004</xref>; <xref ref-type="bibr" rid="bibr37-0192623312464309">Urbich and Dimmeler 2004</xref>).  It has been proposed that VEGFR2 is the earliest EC marker that is expressed, followed closely by CD31 (<xref ref-type="bibr" rid="bibr22-0192623312464309">Kanayasu-Toyoda et al. 2003</xref>; <xref ref-type="bibr" rid="bibr16-0192623312464309">Hristov and Weber 2004</xref>). </p>
<p>Recently, the contribution of myeloid lineage cells in angiogenesis has been reported. <xref ref-type="bibr" rid="bibr40-0192623312464309">Yoder et al. (2007</xref>) showed that cells expressing CD45 and CD14 (monocyte/macrophage cell surface antigen) also expressed EC markers, such as CD31, VEGFR2, and factor VIII–related antigen, and Ulex europaeus agglutinin-1 (UEA-1). <xref ref-type="bibr" rid="bibr23-0192623312464309">Kim et al. (2009</xref>) demonstrated that macrophages (differentiated monocytes) that expressed both CD31 and F4/80 (macrophage cell surface antigen) directly contributed to angiogenesis.</p>
<p>In humans, <xref ref-type="bibr" rid="bibr41-0192623312464309">Yonemori et al. (2011</xref>) reported that another hematopoietic stem cell marker c-kit expression was observed in hemangiosarcomas (15%). Although the sample number is small due to only case reports being available, CD45 expression has been shown to be negative in hemangiosarcomas (<xref ref-type="bibr" rid="bibr26-0192623312464309">Lin et al. 1997</xref>; <xref ref-type="bibr" rid="bibr7-0192623312464309">Forton, Van Parys, and Hertveldt 2005</xref>; <xref ref-type="bibr" rid="bibr24-0192623312464309">Kuroda et al. 2009</xref>; <xref ref-type="bibr" rid="bibr36-0192623312464309">Terada 2011</xref>). CD34, VEGFR2, CD31, and factor VIII–related antigen expression has been demonstrated in hemangiosarcomas and hemangiomas (<xref ref-type="bibr" rid="bibr32-0192623312464309">Poblet, Gonzalez-Palacios, and Jimenez 1996</xref>; <xref ref-type="bibr" rid="bibr1-0192623312464309">Breiteneder-Geleff et al. 1999</xref>; <xref ref-type="bibr" rid="bibr17-0192623312464309">Itakura et al. 2008</xref>; <xref ref-type="bibr" rid="bibr41-0192623312464309">Yonemori et al. 2011</xref>). Although the contribution of myeloid lineage cells to the formation of hemangiosarcomas in humans is unknown, coexpression of CD83 (dendritic cell marker) and EC markers (factor VIII–related antigen or UEA-1) was observed in infantile hemangiomas (<xref ref-type="bibr" rid="bibr33-0192623312464309">Ritter et al. 2006</xref>). This suggests the participation of myeloid-derived cells in the formation of these benign tumors arising from ECs in humans. Canine hemangiosarcoma cell lines expressed c-kit, CD133, CD34, and in some cases, CD45 and CD14 (<xref ref-type="bibr" rid="bibr25-0192623312464309">Lamerato-Kozicki et al. 2006</xref>). However, to the best of our knowledge, there is no literature regarding the expression of hematopoietic stem cell, EC, and myeloid lineage cell antigens in canine hemangiosarcomas/hemangiomas <italic>in vivo</italic>. In spontaneous hemangiosarcomas in Ink4c/p53-null mice, expression of CD34, VEGFR2, CD31, and factor VIII–related antigen was observed (<xref ref-type="bibr" rid="bibr43-0192623312464309">Zindy et al. 2003</xref>); however, expression of CD133, CD45, and myeloid lineage cell antigens, such as CD14, in mouse hemangiomas or hemangiosarcomas has not been extensively investigated.</p>
<p>In the present study, we evaluated the staining of hematopoietic stem cell markers (CD133, CD45, and CD34), EC markers (VEGFR2, CD31, and factor VIII–related antigen), and a myeloid lineage cell marker (CD14) in spontaneous hemangiosarcomas and hemangiomas and in nongenotoxic and genotoxic chemically induced hemangiosarcomas and hemangiomas in mice. These tumors were also stained with the p53 tumor suppressor protein. These results contribute to the understanding of whether the recruitment of hematopoietic stem cells/EPCs and/or myeloid lineage cells are involved in hemangiosarcomas or hemangiomas in mice similar to that previously demonstrated in human hemangiosarcomas (<xref ref-type="bibr" rid="bibr41-0192623312464309">Yonemori et al. 2011</xref>), canine hemangiosarcoma cell lines (<xref ref-type="bibr" rid="bibr25-0192623312464309">Lamerato-Kozicki et al. 2006</xref>), and infantile hemangiomas in humans (<xref ref-type="bibr" rid="bibr33-0192623312464309">Ritter et al. 2006</xref>) or whether differentiated ECs undergo mutations that result in the formation of tumors in mice. </p>
</sec>
<sec id="section2-0192623312464309" sec-type="materials|methods">
<title>Materials and Methods</title>
<sec id="section3-0192623312464309">
<title>Study Design</title>
<p>Paraffin blocks from B6C3F1 mice containing hemangiomas or hemangiosarcomas from various tissues were provided from the archives of the National Institute of Environmental Health Sciences (NIEHS) and Pfizer, Inc., and sectioned for immunohistochemical analysis of CD133, CD45, CD34, VEGFR2, CD31, factor VIII–related antigen, CD14, and p53. Chemical names, exposure routes, genotoxicity of chemicals, dose and duration of treatment, histopathological diagnosis, references, and archive information are described in <xref ref-type="table" rid="table1-0192623312464309">Table 1</xref>. Sex and the number of hemangiosarcomas or hemangiomas for each tissue are described in <xref ref-type="table" rid="table2-0192623312464309">Table 2</xref>. </p>
<table-wrap id="table1-0192623312464309" position="float">
<label>Table 1.</label>
<caption>
<p>Summary of long-term carcinogenicity and genetic toxicity studies.</p>
</caption>
<graphic alternate-form-of="table1-0192623312464309" xlink:href="10.1177_0192623312464309-table1.tif"/>
<table>
<thead>
<tr>
<th>Treatment (exposure route)</th>
<th>Genotoxic or nongenotoxic</th>
<th>Dose</th>
<th>Duration</th>
<th>HS or HA</th>
<th>Reference<sup>a</sup>
</th>
<th>Archive</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td align="center">–</td>
<td align="center">–</td>
<td align="center">–</td>
<td>HS/HA</td>
<td align="center">–</td>
<td>NIEHS, Pfizer, Inc.</td>
</tr>
<tr>
<td>Cupferron (Feed)</td>
<td>Genotoxic</td>
<td>0.4%</td>
<td>78 wks</td>
<td>HS/HA</td>
<td>TR-100</td>
<td>NIEHS</td>
</tr>
<tr>
<td>Butadiene (inhalation)</td>
<td>Genotoxic</td>
<td>8000 ppm</td>
<td>M:60 wks, F:61 wks</td>
<td>HS</td>
<td>TR-288</td>
<td>NIEHS</td>
</tr>
<tr>
<td>Riddelliine (gavage)</td>
<td>Genotoxic</td>
<td>3 mg/kg</td>
<td>2 years</td>
<td>HS</td>
<td>TR-508</td>
<td>NIEHS</td>
</tr>
<tr>
<td>Chloroprene (inhalation)</td>
<td>Nongenotoxic</td>
<td>80 ppm</td>
<td>2 years</td>
<td>HS/HA</td>
<td>TR-467</td>
<td>NIEHS</td>
</tr>
<tr>
<td>2-Butoxyethanol (inhalation)</td>
<td>Nongenotoxic</td>
<td>250 ppm</td>
<td>2 years</td>
<td>HS</td>
<td>TR-484</td>
<td>NIEHS</td>
</tr>
<tr>
<td>Formamide (gavage)</td>
<td>Nongenotoxic</td>
<td>20, 40, and 80 mg/kg</td>
<td>2 years</td>
<td>HS</td>
<td>TR-541</td>
<td>NIEHS</td>
</tr>
<tr>
<td>Troglitazone (gavage)</td>
<td>Nongenotoxic</td>
<td>800 mg/kg</td>
<td>2 years</td>
<td>HS/HA</td>
<td>Herman et al. <xref ref-type="bibr" rid="bibr12-0192623312464309">2002</xref>
</td>
<td>Pfizer, Inc.</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-0192623312464309">
<p>
<italic>Note:</italic> HS = hemangiosarcomas; HA = hemangioma.</p>
</fn>
<fn id="table-fn2-0192623312464309">
<p>
<sup>a</sup> National Toxicology Program (NTP) study report number available at http://ntp.niehs.nih.gov/?objectid=720160DB-BDB7-CEBA-F7CC2DE0A230C920 or peer-reviewed publication.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="table2-0192623312464309" position="float">
<label>Table 2.</label>
<caption>
<p>Summary of the tissues examined in the present study.</p>
</caption>
<graphic alternate-form-of="table2-0192623312464309" xlink:href="10.1177_0192623312464309-table2.tif"/>
<table>
<thead>
<tr>
<th>Treatment</th>
<th>Sex</th>
<th>HS or HA</th>
<th>Organs</th>
<th>Number of samples</th>
</tr>
</thead>
<tbody>
<tr>
<td rowspan="5">Control (spontaneous)</td>
<td rowspan="5">M/F</td>
<td rowspan="2">HA</td>
<td>Liver</td>
<td>3</td>
</tr>
<tr>
<td>Stomach</td>
<td>1</td>
</tr>
<tr>
<td rowspan="3">HS</td>
<td>Adipose tissue</td>
<td>1</td>
</tr>
<tr>
<td>Liver</td>
<td>6</td>
</tr>
<tr>
<td>Spleen</td>
<td>5</td>
</tr>
<tr>
<td rowspan="3">Cupferron</td>
<td>F</td>
<td>HA</td>
<td>Uterus</td>
<td>1</td>
</tr>
<tr>
<td rowspan="2">M/F</td>
<td rowspan="2">HS</td>
<td>Spleen</td>
<td>2</td>
</tr>
<tr>
<td>Subcutaneous</td>
<td>2</td>
</tr>
<tr>
<td>Butadiene</td>
<td>M</td>
<td>HS</td>
<td>Heart</td>
<td>2</td>
</tr>
<tr>
<td rowspan="2">Riddelliine</td>
<td>F</td>
<td>HA</td>
<td>Uterus</td>
<td>1</td>
</tr>
<tr>
<td>M</td>
<td>HS</td>
<td>Liver</td>
<td>2</td>
</tr>
<tr>
<td rowspan="2">Chloroprene</td>
<td rowspan="2">M</td>
<td rowspan="2">HS</td>
<td>Intestine</td>
<td>1</td>
</tr>
<tr>
<td>Liver</td>
<td>3</td>
</tr>
<tr>
<td rowspan="2">2-Butoxyethanol</td>
<td rowspan="2">M</td>
<td>HA</td>
<td>Pancreas</td>
<td>1</td>
</tr>
<tr>
<td>HS</td>
<td>Liver</td>
<td>4</td>
</tr>
<tr>
<td rowspan="4">Formamide</td>
<td rowspan="4">M</td>
<td rowspan="2">HA</td>
<td>Adipose tissue</td>
<td>1</td>
</tr>
<tr>
<td>Heart</td>
<td>1</td>
</tr>
<tr>
<td rowspan="2">HS</td>
<td>Liver</td>
<td>5</td>
</tr>
<tr>
<td>Subcutaneous</td>
<td>1</td>
</tr>
<tr>
<td rowspan="5">Troglitazone</td>
<td rowspan="5">M</td>
<td>HA</td>
<td>Liver</td>
<td>1</td>
</tr>
<tr>
<td rowspan="4">HS</td>
<td>Adipose tissue</td>
<td>1</td>
</tr>
<tr>
<td>Liver</td>
<td>5</td>
</tr>
<tr>
<td>Skin/subcutaneous</td>
<td>5</td>
</tr>
<tr>
<td>Spleen</td>
<td>5</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn3-0192623312464309">
<p>
<italic>Note:</italic> HS = hemangiosarcomas; HA = hemangiomas.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="section4-0192623312464309">
<title>Immunohistochemistry</title>
<p>Immunohistochemical procedures, including antibodies and negative controls for primary antibodies used in our study, are summarized in <xref ref-type="table" rid="table3-0192623312464309">Table 3</xref>. Formalin-fixed and paraffin-embedded mouse tissues were deparaffinized and rehydrated through graded alcohols. Endogenous peroxidase activity was quenched with 3% H<sub>2</sub>O<sub>2</sub>, followed by heat-induced antigen retrieval using a Decloaker pressure chamber (Biocare Medical, Concord, CA) for 5 min at 120<bold>°</bold>C in citrate buffer, pH 6.0 (Biocare Medical) for CD133, CD45, CD34, VEGFR2, CD14, and p53 staining or EDTA, pH 9.0 (Biocare Medical) for CD31 staining, or pepsin retrieval (Biocare Medical) for 3 min at 37<bold>°</bold>C for factor VIII–related antigen staining. Avidin/Biotin Blocking Kit (Vector Laboratories, Burlingame, CA) was used for 15 min at room temperature to block the nonspecific binding of avidin to endogenous biotin, biotin receptors, or avidin-binding sites. Additional blocking of nonspecific binding was performed using 10% normal serum from the host species of the secondary antibody (Jackson ImmunoResearch, West Grove, PA) for 20 min at room temperature for CD133, CD34, VEGFR2, CD31, CD14, and p53 staining or normal serum contained in VECTASTAIN Elite ABC Kit (Rabbit immunoglobulin G [IgG]) purchased from Vector Laboratories for factor VIII–related antigen staining as directed by the manufacturer. No serum block was performed for CD45 staining. Sections were incubated with primary antibodies or negative controls for 1 hr at room temperature. Sections were then incubated with biotinylated donkey anti-rabbit IgG antibody (Jackson ImmunoResearch) for CD133, VEGFR2, and CD14 staining, rabbit anti-rat IgG antibody (Vector Laboratories) for CD34 staining, donkey anti-goat IgG antibody (Jackson) for CD31 staining, or goat anti-rabbit IgG antibody (Vector Laboratories) for p53 staining at a 1:500 dilution. Sections for factor VIII–related antigen staining were incubated with biotinylated secondary antibody contained in VECTASTAIN Elite ABC Kit (Rabbit IgG). The ABC method was used for the detection using VECTASTAIN Elite ABC Reagent (ready-to-use) purchased from Vector Laboratories for CD133, VEGFR2, CD31, CD14, and p53 staining, VECTASTAIN Elite ABC Kit (Rabbit IgG) for factor VIII–related antigen staining, and SS HRP Label (peroxidase-conjugated streptavidin) obtained from Biogenex Laboratories (San Ramon, CA) for CD45 and CD34 staining. The antigen–antibody complex was visualized using 3,3-diaminobenzidine (Dako, Carpinteria, CA) and resulted in brown staining. Slides were then counterstained with hematoxylin, dehydrated, and coverslipped. CD133 staining could not be analyzed since optimization of the immunohistochemical method for CD133 staining was not successful. </p>
<table-wrap id="table3-0192623312464309" position="float">
<label>Table 3.</label>
<caption>
<p>Antibodies and negative controls used for immunohistochemistry.</p>
</caption>
<graphic alternate-form-of="table3-0192623312464309" xlink:href="10.1177_0192623312464309-table3.tif"/>
<table>
<thead>
<tr>
<th>Description of antibodies and negative controls</th>
<th>Manufacturer<sup>a</sup>
</th>
<th>Stock concentration of primary antibodies</th>
<th>Antigen retrieval</th>
<th>Protein block</th>
<th>Primary antibody dilution</th>
<th>Secondary antibodies</th>
<th>Internal positive control cells</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rabbit polyclonal anti-PROM1 (CD133) antibody</td>
<td>Abnova (Cat. PAB12663)</td>
<td rowspan="2">0.5 mg/ml</td>
<td rowspan="2">DC/CB</td>
<td rowspan="2">10% Normal donkey serum</td>
<td rowspan="2">1:50, 1:75, and 1:150</td>
<td rowspan="2">Biotinylated donkey anti-rabbit IgG antibody </td>
<td rowspan="2">N/A</td>
</tr>
<tr>
<td>Normal rabbit serum</td>
<td>Jackson ImmunoResearch (Cat. 001-000-001)</td>
</tr>
<tr>
<td>Biotinylated rat monoclonal anti-CD45 antibody</td>
<td>GeneTex (Cat. GTX19592)</td>
<td rowspan="2">0.5 mg/ml</td>
<td rowspan="2">DC/CB</td>
<td rowspan="2">None</td>
<td rowspan="2">1:250</td>
<td rowspan="2">None</td>
<td rowspan="2">Leukocytes</td>
</tr>
<tr>
<td>Not used</td>
<td align="center">---</td>
</tr>
<tr>
<td>Rat monoclonal anti-CD34 antibody</td>
<td>Abcam (Cat. ab8158)</td>
<td rowspan="2">0.1 mg/ml</td>
<td rowspan="2">DC/CB</td>
<td rowspan="2">10% Normal rabbit serum </td>
<td rowspan="2">1:800</td>
<td rowspan="2">Biotinylated rabbit anti-rat IgG antibody</td>
<td rowspan="2">Vascular endothelium</td>
</tr>
<tr>
<td>Normal rat IgG2a</td>
<td>BD Biosciences (Cat. 553927)</td>
</tr>
<tr>
<td>Rabbit monoclonal anti-VEGFR2 antibody</td>
<td>Cell Signaling (Cat. 2479)</td>
<td rowspan="2">Unknown</td>
<td rowspan="2">DC/CB</td>
<td rowspan="2">10% Normal donkey serum </td>
<td rowspan="2">1:200</td>
<td rowspan="2">Biotinylated donkey anti-rabbit IgG antibody</td>
<td rowspan="2">Vascular endothelium</td>
</tr>
<tr>
<td>Normal rabbit serum</td>
<td>Jackson ImmunoResearch (Cat. 001-000-001)</td>
</tr>
<tr>
<td>Goat polyclonal anti-CD31 antibody</td>
<td>Santa Cruz (sc-1506)</td>
<td rowspan="2">0.2 mg/ml</td>
<td rowspan="2">DC/EDTA</td>
<td rowspan="2">10% Normal donkey serum </td>
<td align="center" rowspan="2">1:1500</td>
<td rowspan="2">Biotinylated donkey anti-goat IgG antibody</td>
<td rowspan="2">Vascular endothelium</td>
</tr>
<tr>
<td>Normal goat serum</td>
<td>Jackson ImmunoResearch (Cat. 005-000-001)</td>
</tr>
<tr>
<td>Rabbit polyclonal anti-factor VIII–related antigen (vWF) antibody</td>
<td>Biocare Medical (Cat. CP039C)</td>
<td rowspan="2">10 mg/ml</td>
<td rowspan="2">Pepsin</td>
<td rowspan="2">VECTASTAIN Elite ABC Kit </td>
<td rowspan="2">1:500</td>
<td rowspan="2">VECTASTAIN Elite ABC Kit</td>
<td rowspan="2">Vascular endothelium</td>
</tr>
<tr>
<td>Normal rat IgG2a</td>
<td>BD Biosciences (Cat. 553927)</td>
</tr>
<tr>
<td>Rabbit polyclonal anti-CD14 antibody</td>
<td>Santa Cruz (Cat. Sc-9150)</td>
<td rowspan="2">0.2 mg/ml</td>
<td rowspan="2">DC/CB</td>
<td rowspan="2">10% Normal donkey serum </td>
<td rowspan="2">1:300</td>
<td rowspan="2">Biotinylated donkey anti-rabbit IgG antibody</td>
<td rowspan="2">Neutrophils</td>
</tr>
<tr>
<td>Normal rabbit serum</td>
<td>Jackson ImmunoResearch (Cat. 001-000-001)</td>
</tr>
<tr>
<td>Rabbit polyclonal anti-p53 antibody</td>
<td>Vector Laboratories (Cat. VP-P956)</td>
<td rowspan="2">Unknown</td>
<td rowspan="2">DC/CB</td>
<td rowspan="2">10% Normal goat serum </td>
<td rowspan="2">1:300</td>
<td rowspan="2">Biotinylated Goat anti-rabbit IgG antibody</td>
<td rowspan="2">Tumor cells</td>
</tr>
<tr>
<td>Normal rat IgG2a</td>
<td>BD Biosciences (Cat. 553927)</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn4-0192623312464309">
<p>
<italic>Note:</italic> DC = Decloaker pressure chamber; CB = citrate buffer (pH 6.0); IgG, immunoglobulin G; vWF = von Willebrand factor; VEGFR2, Vascular endothelial growth factor receptor 2.</p>
</fn>
<fn id="table-fn5-0192623312464309">
<p>
<sup>a</sup> Abcam: Cambridge, MA; Abnova: Walnut, CA; BD Biosciences: San Diego, CA; Biocare Medical: Concord, CA; Cell Signaling: Danvers, MA; GeneTex: Irvine, CA; Jackson ImmunoResearch: West Grove, PA; Vector Laboratories: Burlingame, CA.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="section5-0192623312464309">
<title>Immunohistochemical Evaluation</title>
<p>Immunohistochemically stained sections were semiquantitatively evaluated for the presence/absence of staining, the percentage of tumor cells expressing positive staining, and the overall staining intensity of positively stained tumor cells, and were subsequently classified into one of the following three grades: (−) =  no positive staining in any of the tumor cells; (+) = positive staining in ≤25% of the tumor cells and/or minimal to mild staining intensity; and (++) = positive staining in &gt;25% of the tumor cells and/or moderate to marked staining intensity.</p>
</sec>
<sec id="section6-0192623312464309">
<title>Statistical Analysis</title>
<p>All statistical analyses were performed using Prism 5.01 (GraphPad software, La Jolla, CA). Fisher’s exact test was used to examine the correlation of staining between spontaneous and nongenotoxic chemically induced hemangiosarcomas, between spontaneous and genotoxic chemically induced hemangiosarcomas, between nongenotoxic and genotoxic chemically induced hemangiosarcomas, between spontaneous hemangiomas and chemically induced hemangiomas, and between hemangiomas and hemangiosarcomas. A probability of chance less than 5% was considered as significant.</p>
</sec>
</sec>
<sec id="section7-0192623312464309">
<title>Results</title>
<p>Hemangiosarcomas and hemangiomas collected from mice treated with or without nongenotoxic or genotoxic chemicals were immunostained with hematopoietic stem cell markers (CD133, CD45, and CD34), EC markers (VEGFR2, CD31, and factor VIII–related antigen), and a myeloid lineage cell marker (CD14) to investigate whether these tumors originate from differentiated ECs or stem cells/EPCs in mice. We also investigated the expression of the p53 tumor suppressor protein in these tumors. For each immunostain, no major differences were observed between males and females or between different tissues containing the vascular tumors, in terms of staining pattern and/or intensity (data not shown).</p>
<sec id="section8-0192623312464309">
<title>Hematopoietic Stem Markers</title>
<p>All hemangiosarcomas and hemangiomas were negative for CD45 staining (<xref ref-type="fig" rid="fig1-0192623312464309">Figures 1A</xref> and <xref ref-type="fig" rid="fig4-0192623312464309">4A</xref>, <xref ref-type="table" rid="table4-0192623312464309">Tables 4</xref> and <xref ref-type="table" rid="table5-0192623312464309">5</xref>), despite positive membrane staining of internal control cells (leukocytes) within these sections. In contrast, both spontaneous and chemically induced hemangiosarcomas and hemangiomas were positive for CD34 staining, exhibiting intense membrane staining of a majority of the tumor cells (<xref ref-type="fig" rid="fig2-0192623312464309">Figures 2A</xref> and <xref ref-type="fig" rid="fig3-0192623312464309">3A</xref>, <xref ref-type="table" rid="table4-0192623312464309">Tables 4</xref> and <xref ref-type="table" rid="table5-0192623312464309">5</xref>).  Expression of CD34 is considered to diminish along the cascade of development from early EPCs through differentiated ECs (<xref ref-type="bibr" rid="bibr16-0192623312464309">Hristov and Weber 2004</xref>; <xref ref-type="bibr" rid="bibr37-0192623312464309">Urbich and Dimmeler 2004</xref>). In most instances in our study, tumor cells stained with increased intensity compared to the adjacent normal vascular endothelium (data not shown). While many spontaneous and nongenotoxic chemically induced hemangiosarcomas were positive for CD34 staining (90% and 76%, respectively), there was a significant decrease in the percentage of CD34 positively stained tumors (29%) among the genotoxic chemically induced hemangiosarcomas (<xref ref-type="fig" rid="fig2-0192623312464309">Figure 2B</xref>, <xref ref-type="table" rid="table4-0192623312464309">Table 4</xref>). Unfortunately, the staining method for CD133 could not be successfully optimized, and since no alternative antibodies suitable for immunohistochemistry were available, we were not able to analyze CD133 staining.</p>
<fig id="fig1-0192623312464309" position="float">
<label>Figure 1.</label>
<caption>
<p>Immunostains for CD45 (A), vascular endothelial growth factor receptor 2 (VEGFR2) (B), CD31 (C), factor VIII–related antigen (D), and CD14 (E) in spontaneous and chemically induced hemangiosarcomas in mice. Tumor cells were positive for VEGFR2 (B) and CD31 (C). In contrast, staining for CD45 (A), factor VIII–related antigen (D), and CD14 (E) was negative in these tumors despite the positive staining of internal positive control cells (CD45: leukocytes, factor VIII–related antigen: endothelium in normal vasculature, and CD14: neutrophils) indicated by arrows (data not shown for CD14).  Original magnification: 40×.</p>
</caption>
<graphic xlink:href="10.1177_0192623312464309-fig1.tif"/>
</fig>
<fig id="fig2-0192623312464309" position="float">
<label>Figure 2.</label>
<caption>
<p>Immunostains for CD34 (A and B) and p53 (C, D, and E) in mouse hemangiosarcomas induced by formamide (A, C), 2-butoxyethanol (D), or cupferron (B, E). Many spontaneous and nongenotoxic chemically induced hemangiosarcomas were positive for CD34 staining (A). CD34 staining was negative in 5 of 7 genotoxic chemically induced hemangiosarcomas (B) although the positive staining was observed in the adjacent normal vascular endothelium (data not shown). Sections stained with p53 exhibited a nonspecific hepatocellular cytoplasm; however, specific intense nuclear positive staining was observed in some spontaneous and chloroprene- and formamide-induced hemangiosarcomas (C). p53 staining was negative in troglitazone- and 2-butoxyethanol-induced hemangiosarcomas (D). p53 staining was also negative in genotoxic chemically induced hemangiosarcomas (E). Original magnification: 40×. </p>
</caption>
<graphic xlink:href="10.1177_0192623312464309-fig2.tif"/>
</fig>
<fig id="fig3-0192623312464309" position="float">
<label>Figure 3.</label>
<caption>
<p>Immunostains for CD34 (A), vascular endothelial growth factor receptor 2 (VEGFR2) (B), and CD31 (C) in spontaneous and chemically induced hemangiomas in mice. Tumor cells were positive for CD34 (A), VEGFR2 (B), and CD31 (C).  Original magnification: 40×.</p>
</caption>
<graphic xlink:href="10.1177_0192623312464309-fig3.tif"/>
</fig>
<fig id="fig4-0192623312464309" position="float">
<label>Figure 4.</label>
<caption>
<p>Immunostains for CD45 (A), factor VIII–related antigen (B), CD14 (C), and p53 (D) in spontaneous and chemically induced hemangiomas in mice. Staining for CD45, factor VIII–related antigen, and CD14 was negative in these tumors despite the positive staining of internal positive control cells (CD45: leukocytes, factor VIII–related antigen, endothelium in normal vasculature, and CD14: neutrophils) indicated by arrows for CD45 (A) and factor VIII–related antigen (B) (data not shown for CD14). p53 staining was also negative in spontaneous and chemically induced hemangiomas (D). Original magnification: 40×.</p>
</caption>
<graphic xlink:href="10.1177_0192623312464309-fig4.tif"/>
</fig>
<table-wrap id="table4-0192623312464309" position="float">
<label>Table 4.</label>
<caption>
<p>Comparison of staining for hematopoietic stem cell markers, EC markers, a myeloid lineage cell marker, and a tumor suppressor protein among spontaneous hemangiosaromas, nongenotoxic chemically induced hemangiosarcomas, and genotoxic chemically induced hemangiosarcomas.</p>
</caption>
<graphic alternate-form-of="table4-0192623312464309" xlink:href="10.1177_0192623312464309-table4.tif"/>
<table>
<thead>
<tr>
<th colspan="2">
</th>
<th>Immunohistochemical evaluation</th>
<th>Spontaneous </th>
<th>Nongenotoxic chemicals</th>
<th>Genotoxic chemicals</th>
</tr>
</thead>
<tbody>
<tr>
<td rowspan="6">Hematopoietic stem cell markers</td>
<td rowspan="3">CD45</td>
<td>Positive</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Negative</td>
<td>9</td>
<td>22</td>
<td>0</td>
</tr>
<tr>
<td>Positive (%)</td>
<td>0.0</td>
<td>0.0</td>
<td>---</td>
</tr>
<tr>
<td rowspan="3">CD34</td>
<td>Positive</td>
<td>9</td>
<td>22</td>
<td>2</td>
</tr>
<tr>
<td>Negative</td>
<td>1</td>
<td>7</td>
<td>5</td>
</tr>
<tr>
<td>Positive (%)</td>
<td>90.0</td>
<td>75.9</td>
<td>28.6<sup>*,#</sup>
</td>
</tr>
<tr>
<td rowspan="9">EC markers</td>
<td rowspan="3">VEGFR2</td>
<td>Positive</td>
<td>10</td>
<td>29</td>
<td>8</td>
</tr>
<tr>
<td>Negative</td>
<td>1</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Positive (%)</td>
<td>90.9</td>
<td>100.0</td>
<td>100.0</td>
</tr>
<tr>
<td rowspan="3">CD31</td>
<td>Positive</td>
<td>10</td>
<td>27</td>
<td>4</td>
</tr>
<tr>
<td>Negative</td>
<td>0</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>Positive (%)</td>
<td>100.0</td>
<td>96.4</td>
<td>100.0</td>
</tr>
<tr>
<td rowspan="3">Factor VIII–related antigen</td>
<td>Positive</td>
<td>1</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Negative</td>
<td>11</td>
<td>29</td>
<td>8</td>
</tr>
<tr>
<td>Positive (%)</td>
<td>8.3</td>
<td>0.0</td>
<td>0.0</td>
</tr>
<tr>
<td rowspan="3">Myeloid lineage cell marker</td>
<td rowspan="3">CD14</td>
<td>Positive</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Negative</td>
<td>1</td>
<td>12</td>
<td>2</td>
</tr>
<tr>
<td>Positive (%)</td>
<td>0.0</td>
<td>0.0</td>
<td>0.0</td>
</tr>
<tr>
<td rowspan="3">Tumor suppressor protein</td>
<td rowspan="3">p53</td>
<td>Positive</td>
<td>2</td>
<td>5</td>
<td>0</td>
</tr>
<tr>
<td>Negative</td>
<td>6</td>
<td>24</td>
<td>8</td>
</tr>
<tr>
<td>Positive (%)</td>
<td>25.0</td>
<td>17.2</td>
<td>0.0</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn6-0192623312464309">
<p>
<italic>Note:</italic> VEGFR2, Vascular endothelial growth factor receptor 2.</p>
</fn>
<fn id="table-fn7-0192623312464309">
<p>*<italic>p</italic> &lt; .05 as compared to spontaneous hemangiosarcomas.</p>
</fn>
<fn id="table-fn8-0192623312464309">
<p>
<sup>#</sup>
<italic>p</italic> &lt; .05 as compared to nongenotoxic chemically induced hemangiosarcomas.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="table5-0192623312464309" position="float">
<label>Table 5.</label>
<caption>
<p>Staining for hematopoietic stem cell markers, EC markers, a myeloid lineage cell marker, and a tumor suppressor protein in spontaneous hemangiomas and chemically induced hemangiomas.</p>
</caption>
<graphic alternate-form-of="table5-0192623312464309" xlink:href="10.1177_0192623312464309-table5.tif"/>
<table>
<thead>
<tr>
<th colspan="2">
</th>
<th>Immunohistochemical evaluation</th>
<th>Spontaneous hemangioma</th>
<th>Chemically induced hemangioma</th>
</tr>
</thead>
<tbody>
<tr>
<td rowspan="6">Hematopoietic stem cell markers</td>
<td rowspan="3">CD45</td>
<td>Positive</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Negative</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>Positive (%)</td>
<td>0.0</td>
<td>0.0</td>
</tr>
<tr>
<td rowspan="3">CD34</td>
<td>Positive</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>Negative</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>Positive (%)</td>
<td>50.0</td>
<td>50.0</td>
</tr>
<tr>
<td rowspan="9">EC markers</td>
<td rowspan="3">VEGFR2</td>
<td>Positive</td>
<td>2</td>
<td>3</td>
</tr>
<tr>
<td>Negative</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Positive (%)</td>
<td>66.7</td>
<td>75.0</td>
</tr>
<tr>
<td rowspan="3">CD31</td>
<td>Positive</td>
<td>3</td>
<td>3</td>
</tr>
<tr>
<td>Negative</td>
<td>0</td>
<td>2</td>
</tr>
<tr>
<td>Positive (%)</td>
<td>100.0</td>
<td>60.0</td>
</tr>
<tr>
<td rowspan="3">Factor VIII–related antigen</td>
<td>Positive</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Negative</td>
<td>4</td>
<td>4</td>
</tr>
<tr>
<td>Positive (%)</td>
<td>0.0</td>
<td>0.0</td>
</tr>
<tr>
<td rowspan="3">Myeloid lineage cell marker</td>
<td rowspan="3">CD14</td>
<td>Positive</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Negative</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Positive (%)</td>
<td>0.0</td>
<td>0.0</td>
</tr>
<tr>
<td rowspan="3">Tumor suppressor protein</td>
<td rowspan="3">p53</td>
<td>Positive</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>Negative</td>
<td>3</td>
<td>5</td>
</tr>
<tr>
<td>Positive (%)</td>
<td>25.0</td>
<td>0.0</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn9-0192623312464309">
<p>
<italic>Note:</italic> VEGFR2, Vascular endothelial growth factor receptor 2.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="section9-0192623312464309">
<title>EC Markers</title>
<p>Almost all spontaneous, nongenotoxic and genotoxic chemically induced hemangiosarcomas were positive for both VEGFR2 and CD31 staining (<xref ref-type="fig" rid="fig1-0192623312464309">Figure 1B</xref> and C, <xref ref-type="table" rid="table4-0192623312464309">Table 4</xref>).  Similarly, staining for VEGFR2 and CD31 was also present in many spontaneous and chemically induced hemangiomas (<xref ref-type="fig" rid="fig3-0192623312464309">Figure 3B</xref> and C, <xref ref-type="table" rid="table5-0192623312464309">Table 5</xref>). For both immunostains, the reactive tumor cells exhibited intense diffuse staining, and the staining qualities were similar to that of the adjacent normal vascular endothelium. In contrast, factor VIII–related antigen was negative in most hemangiosarcomas and hemangiomas (<xref ref-type="fig" rid="fig1-0192623312464309">Figures 1D</xref> and <xref ref-type="fig" rid="fig4-0192623312464309">4B</xref>, <xref ref-type="table" rid="table4-0192623312464309">Tables 4</xref> and <xref ref-type="table" rid="table5-0192623312464309">5</xref>) although endothelium in the adjacent normal vasculature was positive (internal positive control). </p>
</sec>
<sec id="section10-0192623312464309">
<title>Myeloid Lineage Cell Marker and Tumor Suppressor Protein</title>
<p>Membrane/cytoplasmic staining was observed in neutrophils (a positive internal control); however, all hemangiosarcomas and hemangiomas were negative for CD14 staining (<xref ref-type="fig" rid="fig1-0192623312464309">Figures 1E</xref> and <xref ref-type="fig" rid="fig4-0192623312464309">4C</xref>, <xref ref-type="table" rid="table4-0192623312464309">Tables 4</xref> and <xref ref-type="table" rid="table5-0192623312464309">5</xref>).  p53 staining was observed in some spontaneous and some nongenotoxic chemically induced hemangiosarcomas (tumors from 1 of 4 chloroprene- and 4 of 6 formamide-treated mice, data not shown; <xref ref-type="fig" rid="fig2-0192623312464309">Figure 2C</xref>) but in none of the 2-butoxyethanol and troglitazone-induced hemangiosarcomas (<xref ref-type="fig" rid="fig2-0192623312464309">Figure 2D</xref>). Staining for p53 was also negative in the genotoxic chemically induced hemangiosarcomas (<xref ref-type="fig" rid="fig2-0192623312464309">Figure 2E</xref> and <xref ref-type="table" rid="table4-0192623312464309">Table 4</xref>) and in the spontaneous and chemically induced hemangiomas (<xref ref-type="fig" rid="fig4-0192623312464309">Figure 4D</xref> and <xref ref-type="table" rid="table5-0192623312464309">Table 5</xref>). Sections stained with p53 exhibited a moderate to marked amount of background and nonspecific cytoplasmic staining, especially in hepatocellular cytoplasm.  Thus, staining was considered positive only when specific intense nuclear positive cells were observed.</p>
</sec>
<sec id="section11-0192623312464309">
<title>Comparison of Staining in Hemangiosarcomas and Hemangiomas</title>
<p>Immunohistochemical staining of hematopoietic stem cell markers (CD45 and CD34), EC markers (VEGFR2, CD31, and factor VIII–related antigen), a myeloid lineage cell marker (CD14), and a tumor suppressor protein (p53) in spontaneous and chemically induced hemangiosarcomas in mice was compared with the staining of these markers in spontaneous and chemically induced hemangiomas in mice. No statistical differences were observed with the exception of an increased percentage of VEGFR2-positive hemangiosarcomas (<xref ref-type="table" rid="table6-0192623312464309">Table 6</xref>). However, this statistical difference might be attributed to the small sample size of hemangiomas present in this study.</p>
<table-wrap id="table6-0192623312464309" position="float">
<label>Table 6.</label>
<caption>
<p>Comparison of staining for hematopoietic stem cell markers, EC markers, a myeloid lineage cell marker, and a tumor suppressor protein in hemangiomas and hemangiosarcomas.</p>
</caption>
<graphic alternate-form-of="table6-0192623312464309" xlink:href="10.1177_0192623312464309-table6.tif"/>
<table>
<thead>
<tr>
<th colspan="2">
</th>
<th>Immunohistochemical evaluation</th>
<th>Spontaneous and chemically induced hemangiomas</th>
<th>Spontaneous and chemically induced hemangiosarcomas</th>
</tr>
</thead>
<tbody>
<tr>
<td rowspan="6">Hematopoietic stem cell markers</td>
<td rowspan="3">CD45</td>
<td>Positive</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Negative</td>
<td>4</td>
<td>31</td>
</tr>
<tr>
<td>Positive (%)</td>
<td>0.0</td>
<td>0.0</td>
</tr>
<tr>
<td rowspan="3">CD34</td>
<td>Positive</td>
<td>4</td>
<td>33</td>
</tr>
<tr>
<td>Negative</td>
<td>4</td>
<td>13</td>
</tr>
<tr>
<td>Positive (%)</td>
<td>50.0</td>
<td>71.7</td>
</tr>
<tr>
<td rowspan="9">EC markers</td>
<td rowspan="3">VEGFR2</td>
<td>Positive</td>
<td>5</td>
<td>47</td>
</tr>
<tr>
<td>Negative</td>
<td>2</td>
<td>1</td>
</tr>
<tr>
<td>Positive (%)</td>
<td>71.4</td>
<td>97.9*</td>
</tr>
<tr>
<td rowspan="3">CD31</td>
<td>Positive</td>
<td>6</td>
<td>41</td>
</tr>
<tr>
<td>Negative</td>
<td>2</td>
<td>1</td>
</tr>
<tr>
<td>Positive (%)</td>
<td>75.0</td>
<td>97.6</td>
</tr>
<tr>
<td rowspan="3">Factor VIII–related antigen</td>
<td>Positive</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>Negative</td>
<td>8</td>
<td>48</td>
</tr>
<tr>
<td>Positive (%)</td>
<td>0.0</td>
<td>2.0</td>
</tr>
<tr>
<td rowspan="3">Myeloid lineage cell marker</td>
<td rowspan="3">CD14</td>
<td>Positive</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Negative</td>
<td>2</td>
<td>15</td>
</tr>
<tr>
<td>Positive (%)</td>
<td>0.0</td>
<td>0.0</td>
</tr>
<tr>
<td rowspan="3">Tumor suppressor protein</td>
<td rowspan="3">p53</td>
<td>Positive</td>
<td>1</td>
<td>7</td>
</tr>
<tr>
<td>Negative</td>
<td>8</td>
<td>38</td>
</tr>
<tr>
<td>Positive (%)</td>
<td>11.1</td>
<td>15.6</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn10-0192623312464309">
<p>
<italic>Note:</italic> VEGFR2, Vascular endothelial growth factor receptor 2.</p>
</fn>
<fn id="table-fn11-0192623312464309">
<p>*<italic>p</italic> &lt; .05 as compared to spontaneous and chemically induced hemangiomas.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
</sec>
<sec id="section12-0192623312464309">
<title>Discussion</title>
<p>Vascular tumors occur spontaneously at relatively high incidences in several mouse strains compared with the incidences in rats (less than 1%; National Toxicology Program [NTP] 2000) and humans (&lt;0.001%; <xref ref-type="bibr" rid="bibr39-0192623312464309">Weiss and Goldblum 2008</xref>), including B6C3F1 mice used in the present studies. According to NTP historical control information for B6C3F1 mice, the mean incidences of spontaneous hemangiosarcoma formation are 9.6% in the male and 3.0% in the female (ranges of 6–14% and 0–14%, respectively) in all organs combined (<xref ref-type="bibr" rid="bibr30-0192623312464309">National Toxicology Program 2000</xref>). These vascular tumors occur in a variety of tissues, especially the liver, spleen, and bone marrow, frequently with multiple tissues being involved in an individual mouse. The incidence of these vascular tumors can be increased by a variety of chemicals, genotoxic or nongenotoxic (<xref ref-type="bibr" rid="bibr3-0192623312464309">Cohen et al. 2009</xref>). The relevance of these mouse vascular tumors induced by nongenotoxic chemicals to humans has been questioned (<xref ref-type="bibr" rid="bibr3-0192623312464309">Cohen et al. 2009</xref>; <xref ref-type="bibr" rid="bibr19-0192623312464309">Kakiuchi-Kiyota et al. 2009</xref>; <xref ref-type="bibr" rid="bibr4-0192623312464309">Criswell et al. 2012</xref>).</p>
<p>In the present study, we investigated whether the process of spontaneous and chemically induced hemangiosarcoma and hemangioma formation in mice involves the transformation of differentiated ECs with the ability for proliferation or multipotential bone marrow–derived hematopoietic stem cells or EPCs showing some differentiation using immunostaining with three hematopoietic stem cell markers, three EC markers, and a myeloid lineage cell marker.</p>
<p>CD133, CD45, and CD34 are hematopoietic stem cell surface antigens expressed on hematopoietic stem cells and bone marrow–derived EPCs. It is considered that CD133 is expressed on more immature cells, such as hematopoietic stem cells and early EPCs located in the bone marrow or in blood just after migration into the circulation (<xref ref-type="bibr" rid="bibr16-0192623312464309">Hristov and Weber 2004</xref>; <xref ref-type="bibr" rid="bibr37-0192623312464309">Urbich and Dimmeler 2004</xref>). Expression of CD133 is decreased in late progenitor cells and absent in mature ECs (<xref ref-type="bibr" rid="bibr9-0192623312464309">Handgretinger et al. 2003</xref>). In contrast, expression of CD34 is not restricted to hematopoietic stem cells or early EPCs but is also present on late EPCs and mature ECs at lower levels compared with EPCs (<xref ref-type="bibr" rid="bibr16-0192623312464309">Hristov and Weber 2004</xref>; <xref ref-type="bibr" rid="bibr37-0192623312464309">Urbich and Dimmeler 2004</xref>). CD45 is expressed not only on hematopoietic stem cells but also on lymphoid and myeloid cell lineages from progenitor to mature cells as a pan-hematopoietic marker (<xref ref-type="bibr" rid="bibr13-0192623312464309">Hermiston, Xu, and Weiss 2003</xref>; <xref ref-type="bibr" rid="bibr37-0192623312464309">Urbich and Dimmeler 2004</xref>). The cascade of CD45 expression during the differentiation process from hematopoietic stem cells to EPCs is unclear. Among the three EC markers used in our study, VEGFR2 is considered to be expressed the earliest and can be seen in more immature cells that also express CD133 (<xref ref-type="bibr" rid="bibr31-0192623312464309">Peichev et al. 2000</xref>). During the differentiation process, these cells lose CD133 expression and begin to express the EC markers, first CD31 and then factor VIII–related antigen (<xref ref-type="bibr" rid="bibr22-0192623312464309">Kanayasu-Toyoda et al. 2003</xref>; <xref ref-type="bibr" rid="bibr16-0192623312464309">Hristov and Weber 2004</xref>).</p>
<p>In the current study, staining for CD45 was negative in spontaneous and chemically induced hemangiosarcomas and hemangiomas in mice. In contrast, CD34-positive cells were observed in these tumors in mice. Due to technical difficulties, we were unable to analyze staining for CD133. These tumors were positive for VEGFR2 and CD31, however, factor VIII–related antigen staining was negative in both hemangiosarcomas and hemangiomas. The qualitative immunohistochemical staining pattern was similar between male and female mice, in tumors from all tissues examined, in hemangiomas and hemangiosarcomas, and in tumors arising spontaneously (in control mice) or in nongenotoxic or genotoxic chemically induced tumors. The staining for most antigens was also quantitatively similar for these comparisons, with the exception of  decreased staining for CD34 in tumors from mice treated with genotoxic chemicals compared to controls and those from mice treated with nongenotoxic chemicals. This might be due to damage to CD34 induced by genotoxic chemicals.</p>
<p>It was reported that &gt;99% of mononuclear cells expressing CD133, CD34, and VEGFR2 in peripheral blood also expressed CD45 (<xref ref-type="bibr" rid="bibr2-0192623312464309">Case et al. 2007</xref>). Without knowing whether tumor cells in our study expressed CD133 in addition to CD34 and VEGFR2, we are unable to speculate further regarding CD45-positive cells. Expression of CD34 is considered to diminish along the progression of development from early EPCs through differentiated ECs (<xref ref-type="bibr" rid="bibr16-0192623312464309">Hristov and Weber 2004</xref>; <xref ref-type="bibr" rid="bibr37-0192623312464309">Urbich and Dimmeler 2004</xref>). In most cases in our study, tumor cells stained with increased intensity compared to the adjacent normal vascular endothelium. Based on the increased intensity of CD34 staining and the lack of factor VIII–related antigen staining in these tumors, these cells may be early EPCs that are not completely differentiated. It is still unclear whether circulating early EPCs directly contributed to the hemangiosarcoma formation or more immature stem cells contributed to the tumor formation and differentiated to EPCs, but then differentiation was arrested at the early EPC stage. </p>
<p>Canine hemangiosarcoma cell lines expressed c-kit and CD133 in addition to CD34 and, in some cases, CD45 (<xref ref-type="bibr" rid="bibr25-0192623312464309">Lamerato-Kozicki et al. 2006</xref>). In humans, some studies have reported that immunostaining in hemangiosarcomas for CD45 was negative and c-kit staining was variable (15%; 5 of 34 samples; <xref ref-type="bibr" rid="bibr26-0192623312464309">Lin, Weiss, and Battifora 1997</xref>; <xref ref-type="bibr" rid="bibr7-0192623312464309">Forton, Van Parys, and Hertveldt 2005</xref>; <xref ref-type="bibr" rid="bibr36-0192623312464309">Terada 2011</xref>; <xref ref-type="bibr" rid="bibr41-0192623312464309">Yonemori et al. 2011</xref>). No reports are available regarding the expression of CD133 in these tumors in humans. These results indicated that more immature stem cells expressing c-kit, CD133, and/or CD45 contributed to hemangiosarcomas in dogs and humans. Expression of CD34, VEGFR2, CD31, factor VIII–related antigen, and other EC markers has been demonstrated in human and canine cases of hemangiosarcomas and/or hemangiomas (<xref ref-type="bibr" rid="bibr38-0192623312464309">von Beust, Suter, and Summers 1988</xref>; <xref ref-type="bibr" rid="bibr32-0192623312464309">Poblet, Gonzalez-Palacios, and Jimenez 1996</xref>; <xref ref-type="bibr" rid="bibr26-0192623312464309">Lin, Weiss, and Battifora 1997</xref>; <xref ref-type="bibr" rid="bibr1-0192623312464309">Breiteneder-Geleff et al. 1999</xref>; <xref ref-type="bibr" rid="bibr7-0192623312464309">Forton, Van Parys, and Hertveldt 2005</xref>; <xref ref-type="bibr" rid="bibr25-0192623312464309">Lamerato-Kozicki et al. 2006</xref>; <xref ref-type="bibr" rid="bibr17-0192623312464309">Itakura et al. 2008</xref>; <xref ref-type="bibr" rid="bibr36-0192623312464309">Terada 2011</xref>; <xref ref-type="bibr" rid="bibr41-0192623312464309">Yonemori et al. 2011</xref>). Considering that factor VIII–related antigen expression, which has been shown to occur later than CD31 expression in EPCs, was also positive in these tumors, it is likely that the tumors arise from more immature cells but retain the ability to more fully differentiate in humans and canines.</p>
<p>CD14 is a monocyte/macrophage cell surface antigen, and the contribution of myeloid lineage cells to angiogenesis has recently been demonstrated (<xref ref-type="bibr" rid="bibr40-0192623312464309">Yoder et al. 2007</xref>; <xref ref-type="bibr" rid="bibr23-0192623312464309">Kim et al. 2009</xref>).  In addition, it was reported that the coexpression of a dendritic cell marker and EC markers was observed in human infantile hemangioma (<xref ref-type="bibr" rid="bibr33-0192623312464309">Ritter et al. 2006</xref>). It is possible that myeloid-derived cells are involved in hemangiosarcoma formation in dogs, at least in some cases (<xref ref-type="bibr" rid="bibr25-0192623312464309">Lamerato-Kozicki et al. 2006</xref>). However, CD14 staining was absent in spontaneous and chemically induced hemangiosarcomas and hemangiomas in mice, indicating that there is no contribution of monocyte-/macrophage-derived cells to tumor formation. </p>
<p>Since the expression pattern of hematopoietic stem cell and EC markers in mouse hemangiosarcomas was similar to mouse hemangiomas in the current study, this may indicate that hemangiosarcomas could arise from benign EC tumors (hemangiomas) in mice. However, it is still questionable since in humans there is no evidence that hemangiosarcomas (rare tumors) arise from hemangiomas (common tumors) or any other benign precursor (<xref ref-type="bibr" rid="bibr3-0192623312464309">Cohen et al. 2009</xref>). </p>
<p>We also investigated p53 expression in hemangiosarcomas and hemangiomas in mice. Wild-type p53 protein has a short half-life; however, the mutated form of p53 protein is stabilized and can be detected in the nucleus of neoplastic cells (<xref ref-type="bibr" rid="bibr15-0192623312464309">Hong et al. 2003</xref>). It is well known in human tumors that inactivation of the tumor suppressor gene, <italic>p53</italic>, is involved in hemangiosarcomas but not hemangiomas. For example, in humans, immunostains for <italic>p53</italic> were almost entirely negative in hemangiomas (<xref ref-type="bibr" rid="bibr18-0192623312464309">Iwata et al. 1996</xref>), whereas nuclei of malignant cells in hemangiosarcomas stained positive for p53 protein (<xref ref-type="bibr" rid="bibr28-0192623312464309">Meis-Kindblom and Kindblom 1998</xref>). Furthermore, p53 protein mutations in exons 5–8 were observed in spontaneous and vinyl chloride–induced hemangiosarcomas in humans (<xref ref-type="bibr" rid="bibr14-0192623312464309">Hollstein et al. 1994</xref>; <xref ref-type="bibr" rid="bibr29-0192623312464309">Naka et al. 1997</xref>). Multiple publications indicate the increased frequency of hemangiosarcoma formation in <italic>p53</italic>-mutant mice (<xref ref-type="bibr" rid="bibr5-0192623312464309">Donehower et al. 1992</xref>; <xref ref-type="bibr" rid="bibr43-0192623312464309">Zindy et al. 2003</xref>). In our study, similar to humans, p53 staining was negative in most hemangioma samples. Staining of p53 in nongenotoxic chemically induced hemangiosarcomas in mice was variable. It was absent in hemangiosarcomas collected from troglitazone-treated mice similar to previous reports (<xref ref-type="bibr" rid="bibr6-0192623312464309">Duddy et al. 1999</xref>), in 2-butoxyethanol-treated mice and in most tumors collected from chloroprene-treated mice. However, immunostaining was observed in 4 of 6 formamide-induced hemangiosarcomas. Wild-type p53 protein can be stabilized and functionally inactivated by binding to the cellular murine double minus-2 (MDM2) protein so that overexpression of MDM2 may inactivate wild-type p53 protein in hemangiosarcomas (<xref ref-type="bibr" rid="bibr42-0192623312464309">Zietz et al. 1998</xref>). Therefore, it is possible that formamide, but not other nongenotoxic chemicals, affected pathways that increase MDM2 protein, resulting in the stabilized p53 without inducing genetic mutation in <italic>p53</italic>.</p>
<p>In summary, this study indicates that the hemangiosarcomas and hemangiomas in mice are composed of EPCs expressing CD34, VEGFR2, and CD31 but not factor VIII–related antigen. Hematopoietic stem cell antigen, CD45, was negative, and myeloid-lineage cells do not appear to contribute to hemangiosarcoma and hemangioma formation in mice. The lack of factor VIII–related antigen expression may indicate that the mouse tumor cells are arrested at a stage prior to complete differentiation, although it is likely that tumor cells retain the ability to more fully differentiate in humans and canines. Our results indicate that mouse hemangiomas and hemangiosarcomas may arise by a different mechanism than canine EC tumors and possibly humans, and use of the rodent model for understanding the mechanism and relevance of EC tumors to humans might not be appropriate. Additional studies better defining the immunophenotype of vascular tumors are required.</p>
</sec>
</body>
<back>
<ack>
<title>Acknowledgments</title>
<p>The authors gratefully acknowledge Dr. Norimitsu Shirai at Pfizer, Inc., for his pathological expertise and the individuals at EPL, Inc.:  the Histology Lab for retrieving the paraffin blocks and cutting sections, the Photo Lab for taking photos of immunostaining, and Beth Mahler for editing images. We also gratefully acknowledge the technical expertise of Heather Jensen, Otis Lyght, Geoffrey Hurlburt, Yvette Rebolloso, David Olson, Quashana Brown, and Natasha Clayton in the Immunohistochemistry Lab of the Pathology Support Group of the Cellular and Molecular Pathology Branch of the National Toxicology Program, NIEHS for development of the methodology and performance of the immunohistochemistry. Heather Jensen was particularly helpful technically and in assisting in preparation of the manuscript. This research was supported (in part) by the Division of the National Toxicology Program of the NIH, National Institute of Environmental Health Sciences. This article may be the work product of an employee or group of employees of the National Institute of Environmental Health Sciences (NIEHS), National Institutes of Health (NIH); however, the statements, opinions, or conclusions contained therein do not necessarily represent the statements, opinions, or conclusions of NIEHS, NIH, or the U.S. government.</p>
</ack>
<fn-group>
<fn fn-type="conflict" id="fn1-0192623312464309">
<p>Drs. Kakiuchi-Kiyota and Cook work for Pfizer, Inc.; Dr. Crabbs works for EPL, Inc., with a previous appointment at the National Toxicology Program; and Dr. Cohen has consulted for Pfizer.</p>
</fn>
<fn fn-type="financial-disclosure" id="fn2-0192623312464309">
<p>The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This research was supported in part by the Division of the National Toxicology Program of the NIH, National Institute of Environmental Health Sciences; however, the statements, opinions or conclusions contained therein do not necessarily represent the statements, opinions, or conclusions of NIEHS, NIH, or the U.S. government.</p>
</fn>
</fn-group>
<glossary content-type="abbr">
<title>Abbreviations</title>
<def-list>
<def-item>
<term id="term1-0192623312464309">EC</term>
<def>
<p>endothelial cell</p>
</def>
</def-item>
<def-item>
<term id="term2-0192623312464309">EPC</term>
<def>
<p>endothelial progenitor cell</p>
</def>
</def-item>
<def-item>
<term id="term3-0192623312464309">PPAR</term>
<def>
<p>peroxisome proliferator–activated receptor</p>
</def>
</def-item>
<def-item>
<term id="term4-0192623312464309">UEA-1</term>
<def>
<p>ulex europaeus agglutinin-1</p>
</def>
</def-item>
<def-item>
<term id="term5-0192623312464309">VEGFR2</term>
<def>
<p>vascular endothelial growth factor receptor 2</p>
</def>
</def-item>
<def-item>
<term id="term6-0192623312464309">vWF</term>
<def>
<p>von Willebrand factor</p>
</def>
</def-item>
</def-list>
</glossary>
<ref-list>
<title>References</title>
<ref id="bibr1-0192623312464309">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Breiteneder-Geleff</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Soleiman</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Kowalski</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Horvat</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Amann</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Kriehuber</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Diem</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Weninger</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Tschachler</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Alitalo</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Kerjaschki</surname>
<given-names>D.</given-names>
</name>
</person-group> (<year>1999</year>). <article-title>Angiosarcomas express mixed endothelial phenotypes of blood and lymphatic capillaries: Podoplanin as a specific marker for lymphatic endothelium</article-title>. <source>Am J Pathol</source> <volume>154</volume>, <fpage>385</fpage>–<lpage>94</lpage>.</citation>
</ref>
<ref id="bibr2-0192623312464309">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Case</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Mead</surname>
<given-names>L. E.</given-names>
</name>
<name>
<surname>Bessler</surname>
<given-names>W. K.</given-names>
</name>
<name>
<surname>Prater</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>White</surname>
<given-names>H. A.</given-names>
</name>
<name>
<surname>Saadatzadeh</surname>
<given-names>M. R.</given-names>
</name>
<name>
<surname>Bhavsar</surname>
<given-names>J. R.</given-names>
</name>
<name>
<surname>Yoder</surname>
<given-names>M. C.</given-names>
</name>
<name>
<surname>Haneline</surname>
<given-names>L. S.</given-names>
</name>
<name>
<surname>Ingram</surname>
<given-names>D. A.</given-names>
</name>
</person-group> (<year>2007</year>). <article-title>Human CD34+AC133+VEGFR-2+ cells are not endothelial progenitor cells but distinct, primitive hematopoietic progenitors</article-title>. <source>Exp Hematol</source> <volume>35</volume>, <fpage>1109</fpage>–<lpage>18</lpage>.</citation>
</ref>
<ref id="bibr3-0192623312464309">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cohen</surname>
<given-names>S. M.</given-names>
</name>
<name>
<surname>Storer</surname>
<given-names>R. D.</given-names>
</name>
<name>
<surname>Criswell</surname>
<given-names>K. A.</given-names>
</name>
<name>
<surname>Doerrer</surname>
<given-names>N. G.</given-names>
</name>
<name>
<surname>Dellarco</surname>
<given-names>V. L.</given-names>
</name>
<name>
<surname>Pegg</surname>
<given-names>D. G.</given-names>
</name>
<name>
<surname>Wojcinski</surname>
<given-names>Z. W.</given-names>
</name>
<name>
<surname>Malarkey</surname>
<given-names>D. E.</given-names>
</name>
<name>
<surname>Jacobs</surname>
<given-names>A. C.</given-names>
</name>
<name>
<surname>Klaunig</surname>
<given-names>J. E.</given-names>
</name>
<name>
<surname>Swenberg</surname>
<given-names>J. A.</given-names>
</name>
<name>
<surname>Cook</surname>
<given-names>J. C.</given-names>
</name>
</person-group> (<year>2009</year>). <article-title>Hemangiosarcoma in rodents: Mode-of-action evaluation and human relevance</article-title>. <source>Toxicol Sci</source> <volume>111</volume>, <fpage>4</fpage>–<lpage>18</lpage>.</citation>
</ref>
<ref id="bibr4-0192623312464309">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Criswell</surname>
<given-names>K. A.</given-names>
</name>
<name>
<surname>Wojcinski</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Pegg</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Herman</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Anderson</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Wesche</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Giddings</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Brady</surname>
<given-names>J. T.</given-names>
</name>
<name>
<surname>Cook</surname>
<given-names>J. C.</given-names>
</name>
</person-group> (<year>2012</year>). <article-title>Mode of action associated with development of hemangiosarcoma in mice given pregabalin and assessment of human relevance</article-title>. <source>Toxicol Sci</source> <volume>128</volume>, <fpage>57</fpage>–<lpage>71</lpage>.</citation>
</ref>
<ref id="bibr5-0192623312464309">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Donehower</surname>
<given-names>L. A.</given-names>
</name>
<name>
<surname>Harvey</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Slagle</surname>
<given-names>B. L.</given-names>
</name>
<name>
<surname>McArthur</surname>
<given-names>M. J.</given-names>
</name>
<name>
<surname>Montgomery</surname>
<given-names>C. A.</given-names>
<suffix>Jr</suffix>
</name>
<name>
<surname>Butel</surname>
<given-names>J. S.</given-names>
</name>
<name>
<surname>Bradley</surname>
<given-names>A.</given-names>
</name>
</person-group> (<year>1992</year>). <article-title>Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours</article-title>. <source>Nature</source> <volume>356</volume>, <fpage>215</fpage>–<lpage>21</lpage>.</citation>
</ref>
<ref id="bibr6-0192623312464309">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Duddy</surname>
<given-names>S. K.</given-names>
</name>
<name>
<surname>Parker</surname>
<given-names>R. F.</given-names>
</name>
<name>
<surname>Bleavins</surname>
<given-names>M. R.</given-names>
</name>
<name>
<surname>Gough</surname>
<given-names>A. W.</given-names>
</name>
<name>
<surname>Rowse</surname>
<given-names>P. E.</given-names>
</name>
<name>
<surname>Gorospe</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Dethloff</surname>
<given-names>L. A.</given-names>
</name>
<name>
<surname>de la Iglesia</surname>
<given-names>F. A.</given-names>
</name>
</person-group> (<year>1999</year>). <article-title>p53 is not inactivated in B6C3F1 mouse vascular tumors arising spontaneously or associated with long-term administration of the thiazolidinedione troglitazone</article-title>. <source>Toxicol Appl Pharmacol</source> <volume>156</volume>, <fpage>106</fpage>–<lpage>12</lpage>.</citation>
</ref>
<ref id="bibr7-0192623312464309">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Forton</surname>
<given-names>G. E.</given-names>
</name>
<name>
<surname>Van Parys</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Hertveldt</surname>
<given-names>K.</given-names>
</name>
</person-group> (<year>2005</year>). <article-title>Primary angiosarcoma of the non-irradiated parotid gland: A most uncommon, highly malignant tumor</article-title>. <source>Eur Arch Otorhinolaryngol</source> <volume>262</volume>, <fpage>173</fpage>–<lpage>77</lpage>.</citation>
</ref>
<ref id="bibr8-0192623312464309">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gehling</surname>
<given-names>U. M.</given-names>
</name>
<name>
<surname>Ergun</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Schumacher</surname>
<given-names>U.</given-names>
</name>
<name>
<surname>Wagener</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Pantel</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Otte</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Schuch</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Schafhausen</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Mende</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Kilic</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Kluge</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Schafer</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Hossfeld</surname>
<given-names>D. K.</given-names>
</name>
<name>
<surname>Fiedler</surname>
<given-names>W.</given-names>
</name>
</person-group> (<year>2000</year>). <article-title>In vitro differentiation of endothelial cells from AC133-positive progenitor cells</article-title>. <source>Blood</source> <volume>95</volume>, <fpage>3106</fpage>–<lpage>12</lpage>.</citation>
</ref>
<ref id="bibr9-0192623312464309">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Handgretinger</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Gordon</surname>
<given-names>P. R.</given-names>
</name>
<name>
<surname>Leimig</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Buhring</surname>
<given-names>H. J.</given-names>
</name>
<name>
<surname>Niethammer</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Kuci</surname>
<given-names>S.</given-names>
</name>
</person-group> (<year>2003</year>). <article-title>Biology and plasticity of CD133+ hematopoietic stem cells</article-title>. <source>Ann N Y Acad Sci</source> <volume>996</volume>, <fpage>141</fpage>–<lpage>51</lpage>.</citation>
</ref>
<ref id="bibr10-0192623312464309">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Harach</surname>
<given-names>H. R.</given-names>
</name>
<name>
<surname>Jasani</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Williams</surname>
<given-names>E. D.</given-names>
</name>
</person-group> (<year>1983</year>). <article-title>Factor VIII as a marker of endothelial cells in follicular carcinoma of the thyroid</article-title>. <source>J Clin Pathol</source> <volume>36</volume>, <fpage>1050</fpage>–<lpage>54</lpage>.</citation>
</ref>
<ref id="bibr11-0192623312464309">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hardisty</surname>
<given-names>J. F.</given-names>
</name>
<name>
<surname>Elwell</surname>
<given-names>M. R.</given-names>
</name>
<name>
<surname>Ernst</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Greaves</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Kolenda-Roberts</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Malarkey</surname>
<given-names>D. E.</given-names>
</name>
<name>
<surname>Mann</surname>
<given-names>P. C.</given-names>
</name>
<name>
<surname>Tellier</surname>
<given-names>P. A.</given-names>
</name>
</person-group> (<year>2007</year>). <article-title>Histopathology of hemangiosarcomas in mice and hamsters and liposarcomas/fibrosarcomas in rats associated with PPAR agonists</article-title>. <source>Toxicol Pathol</source> <volume>35</volume>, <fpage>928</fpage>–<lpage>41</lpage>.</citation>
</ref>
<ref id="bibr12-0192623312464309">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Herman</surname>
<given-names>J. R.</given-names>
</name>
<name>
<surname>Dethloff</surname>
<given-names>L. A.</given-names>
</name>
<name>
<surname>McGuire</surname>
<given-names>E. J.</given-names>
</name>
<name>
<surname>Parker</surname>
<given-names>R. F.</given-names>
</name>
<name>
<surname>Walsh</surname>
<given-names>K. M.</given-names>
</name>
<name>
<surname>Gough</surname>
<given-names>A. W.</given-names>
</name>
<name>
<surname>Masuda</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>de la Iglesia</surname>
<given-names>F. A.</given-names>
</name>
</person-group> (<year>2002</year>). <article-title>Rodent carcinogenicity with the thiazolidinedione antidiabetic agent troglitazone</article-title>. <source>Toxicol Sci</source> <volume>68</volume>, <fpage>226</fpage>–<lpage>36</lpage>.</citation>
</ref>
<ref id="bibr13-0192623312464309">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hermiston</surname>
<given-names>M.L.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Weiss</surname>
<given-names>A.</given-names>
</name>
</person-group> (<year>2003</year>). <article-title>CD45: A critical regulator of signaling thresholds in immune cells</article-title>. <source>Annu Rev Immunol</source> <volume>21</volume>, <fpage>107</fpage>–<lpage>37</lpage>.</citation>
</ref>
<ref id="bibr14-0192623312464309">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hollstein</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Marion</surname>
<given-names>M. J.</given-names>
</name>
<name>
<surname>Lehman</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Welsh</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Harris</surname>
<given-names>C. C.</given-names>
</name>
<name>
<surname>Martel-Planche</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Kusters</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Montesano</surname>
<given-names>R.</given-names>
</name>
</person-group> (<year>1994</year>). <article-title>p53 mutations at A:T base pairs in angiosarcomas of vinyl chloride-exposed factory workers</article-title>. <source>Carcinogenesis</source> <volume>15</volume>, <fpage>1</fpage>–<lpage>3</lpage>.</citation>
</ref>
<ref id="bibr15-0192623312464309">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hong</surname>
<given-names>H. L.</given-names>
</name>
<name>
<surname>Ton</surname>
<given-names>T. V.</given-names>
</name>
<name>
<surname>Devereux</surname>
<given-names>T. R.</given-names>
</name>
<name>
<surname>Moomaw</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Clayton</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Chan</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Dunnick</surname>
<given-names>J. K.</given-names>
</name>
<name>
<surname>Sills</surname>
<given-names>R. C.</given-names>
</name>
</person-group> (<year>2003</year>). <article-title>Chemical-specific alterations in ras, p53, and beta-catenin genes in hemangiosarcomas from B6C3F1 mice exposed to o-nitrotoluene or riddelliine for 2 years</article-title>. <source>Toxicol Appl Pharmacol</source> <volume>191</volume>, <fpage>227</fpage>–<lpage>34</lpage>.</citation>
</ref>
<ref id="bibr16-0192623312464309">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hristov</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Weber</surname>
<given-names>C.</given-names>
</name>
</person-group> (<year>2004</year>). <article-title>Endothelial progenitor cells: Characterization, pathophysiology, and possible clinical relevance</article-title>. <source>J Cell Mol Med</source> <volume>8</volume>, <fpage>498</fpage>–<lpage>508</lpage>.</citation>
</ref>
<ref id="bibr17-0192623312464309">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Itakura</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Yamamoto</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Oda</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Tsuneyoshi</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>2008</year>). <article-title>Detection and characterization of vascular endothelial growth factors and their receptors in a series of angiosarcomas</article-title>. <source>J Surg Oncol</source> <volume>97</volume>, <fpage>74</fpage>–<lpage>81</lpage>.</citation>
</ref>
<ref id="bibr18-0192623312464309">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Iwata</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Sonobe</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Furihata</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Ido</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Ohtsuki</surname>
<given-names>Y.</given-names>
</name>
</person-group> (<year>1996</year>). <article-title>High frequency of apoptosis in infantile capillary haemangioma</article-title>. <source>J Pathol</source> <volume>179</volume>, <fpage>403</fpage>–<lpage>408</lpage>.</citation>
</ref>
<ref id="bibr19-0192623312464309">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kakiuchi-Kiyota</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Vetro</surname>
<given-names>J. A.</given-names>
</name>
<name>
<surname>Suzuki</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Varney</surname>
<given-names>M. L.</given-names>
</name>
<name>
<surname>Han</surname>
<given-names>H. Y.</given-names>
</name>
<name>
<surname>Nascimento</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Pennington</surname>
<given-names>K. L.</given-names>
</name>
<name>
<surname>Arnold</surname>
<given-names>L. L.</given-names>
</name>
<name>
<surname>Singh</surname>
<given-names>R. K.</given-names>
</name>
<name>
<surname>Cohen</surname>
<given-names>S. M.</given-names>
</name>
</person-group> (<year>2009</year>). <article-title>Effects of the PPARgamma agonist troglitazone on endothelial cells in vivo and in vitro: Differences between human and mouse</article-title>. <source>Toxicol Appl Pharmacol</source> <volume>237</volume>, <fpage>83</fpage>–<lpage>90</lpage>.</citation>
</ref>
<ref id="bibr20-0192623312464309">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kakiuchi-Kiyota</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Arnold</surname>
<given-names>L. L.</given-names>
</name>
<name>
<surname>Yokohira</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Koza-Taylor</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Suzuki</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Varney</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Pennington</surname>
<given-names>K. L.</given-names>
</name>
<name>
<surname>Cohen</surname>
<given-names>S. M.</given-names>
</name>
</person-group> (<year>2011a</year>). <article-title>Evaluation of direct and indirect effects of the PPARgamma agonist troglitazone on mouse endothelial cell proliferation</article-title>. <source>Toxicol Pathol</source> <volume>39</volume>, <fpage>1032</fpage>–<lpage>45</lpage>.</citation>
</ref>
<ref id="bibr21-0192623312464309">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kakiuchi-Kiyota</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Arnold</surname>
<given-names>L. L.</given-names>
</name>
<name>
<surname>Yokohira</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Suzuki</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Pennington</surname>
<given-names>K. L.</given-names>
</name>
<name>
<surname>Cohen</surname>
<given-names>S. M.</given-names>
</name>
</person-group> (<year>2011b</year>). <article-title>Evaluation of PPARgamma agonists on rodent endothelial cell proliferation</article-title>. <source>Toxicology</source> <volume>287</volume>, <fpage>91</fpage>–<lpage>98</lpage>.</citation>
</ref>
<ref id="bibr22-0192623312464309">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kanayasu-Toyoda</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Yamaguchi</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Oshizawa</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Hayakawa</surname>
<given-names>T.</given-names>
</name>
</person-group> (<year>2003</year>). <article-title>CD31 (PECAM-1)-bright cells derived from AC133-positive cells in human peripheral blood as endothelial-precursor cells</article-title>. <source>J Cell Physiol</source> <volume>195</volume>, <fpage>119</fpage>–<lpage>29</lpage>.</citation>
</ref>
<ref id="bibr23-0192623312464309">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kim</surname>
<given-names>S. J.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>J. S.</given-names>
</name>
<name>
<surname>Papadopoulos</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Wook Kim</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Maya</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>He</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Fan</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Langley</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Fidler</surname>
<given-names>I. J.</given-names>
</name>
</person-group> (<year>2009</year>). <article-title>Circulating monocytes expressing CD31: Implications for acute and chronic angiogenesis</article-title>. <source>Am J Pathol</source> <volume>174</volume>, <fpage>1972</fpage>–<lpage>80</lpage>.</citation>
</ref>
<ref id="bibr24-0192623312464309">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kuroda</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Hamaguchi</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Inoue</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Ohara</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Mizuno</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Hayashi</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>G. H.</given-names>
</name>
</person-group> (<year>2009</year>). <article-title>Application of immunocytochemistry to the diagnosis of primary epithelioid angiosarcoma of the lung</article-title>. <source>Med Mol Morphol</source> <volume>42</volume>, <fpage>250</fpage>–<lpage>53</lpage>.</citation>
</ref>
<ref id="bibr25-0192623312464309">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lamerato-Kozicki</surname>
<given-names>A. R.</given-names>
</name>
<name>
<surname>Helm</surname>
<given-names>K. M.</given-names>
</name>
<name>
<surname>Jubala</surname>
<given-names>C. M.</given-names>
</name>
<name>
<surname>Cutter</surname>
<given-names>G. C.</given-names>
</name>
<name>
<surname>Modiano</surname>
<given-names>J. F.</given-names>
</name>
</person-group> (<year>2006</year>). <article-title>Canine hemangiosarcoma originates from hematopoietic precursors with potential for endothelial differentiation</article-title>. <source>Exp Hematol</source> <volume>34</volume>, <fpage>870</fpage>–<lpage>878</lpage>.</citation>
</ref>
<ref id="bibr26-0192623312464309">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lin</surname>
<given-names>B. T.</given-names>
</name>
<name>
<surname>Weiss</surname>
<given-names>L. M.</given-names>
</name>
<name>
<surname>Battifora</surname>
<given-names>H.</given-names>
</name>
</person-group> (<year>1997</year>). <article-title>Intravascularly disseminated angiosarcoma: True neoplastic angioendotheliomatosis? Report of two cases</article-title>. <source>Am J Surg Pathol</source> <volume>21</volume>, <fpage>1138</fpage>–<lpage>1143</lpage>.</citation>
</ref>
<ref id="bibr28-0192623312464309">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Meis-Kindblom</surname>
<given-names>J. M.</given-names>
</name>
<name>
<surname>Kindblom</surname>
<given-names>L. G.</given-names>
</name>
</person-group> (<year>1998</year>). <article-title>Angiosarcoma of soft tissue: A study of 80 cases</article-title>. <source>Am J Surg Pathol</source> <volume>22</volume>, <fpage>683</fpage>–<lpage>97</lpage>.</citation>
</ref>
<ref id="bibr29-0192623312464309">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Naka</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Tomita</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Nakanishi</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Araki</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Hongyo</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Ochi</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Aozasa</surname>
<given-names>K.</given-names>
</name>
</person-group> (<year>1997</year>). <article-title>Mutations of p53 tumor-suppressor gene in angiosarcoma</article-title>. <source>Int J Cancer</source> <volume>71</volume>, <fpage>952</fpage>–<lpage>55</lpage>.</citation>
</ref>
<ref id="bibr30-0192623312464309">
<citation citation-type="web">
<collab collab-type="author">National Toxicology Program</collab>, (<year>2000</year>). <comment>NIEHS Internet Website</comment>. <ext-link ext-link-type="uri" xlink:href="http://ntp.niehs.nihgov/index.cfm?objectid=92E6AAA5-F1F6-975E-71C88528A3E7B315#5">http://ntp.niehs.nihgov/index.cfm?objectid=92E6AAA5-F1F6-975E-71C88528A3E7B315#5</ext-link>. <comment>Accessed May 2010</comment>.</citation>
</ref>
<ref id="bibr31-0192623312464309">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Peichev</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Naiyer</surname>
<given-names>A. J.</given-names>
</name>
<name>
<surname>Pereira</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Lane</surname>
<given-names>W. J.</given-names>
</name>
<name>
<surname>Williams</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Oz</surname>
<given-names>M. C.</given-names>
</name>
<name>
<surname>Hicklin</surname>
<given-names>D. J.</given-names>
</name>
<name>
<surname>Witte</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Moore</surname>
<given-names>M. A.</given-names>
</name>
<name>
<surname>Rafii</surname>
<given-names>S.</given-names>
</name>
</person-group> (<year>2000</year>). <article-title>Expression of VEGFR-2 and AC133 by circulating human CD34(+) cells identifies a population of functional endothelial precursors</article-title>. <source>Blood</source> <volume>95</volume>, <fpage>952</fpage>–<lpage>58</lpage>.</citation>
</ref>
<ref id="bibr32-0192623312464309">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Poblet</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Gonzalez-Palacios</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Jimenez</surname>
<given-names>F. J.</given-names>
</name>
</person-group> (<year>1996</year>). <article-title>Different immunoreactivity of endothelial markers in well and poorly differentiated areas of angiosarcomas</article-title>. <source>Virchows Arch</source> <volume>428</volume>, <fpage>217</fpage>–<lpage>21</lpage>.</citation>
</ref>
<ref id="bibr33-0192623312464309">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ritter</surname>
<given-names>M. R.</given-names>
</name>
<name>
<surname>Reinisch</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Friedlander</surname>
<given-names>S. F.</given-names>
</name>
<name>
<surname>Friedlander</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>2006</year>). <article-title>Myeloid cells in infantile hemangioma</article-title>. <source>Am J Pathol</source> <volume>168</volume>, <fpage>621</fpage>–<lpage>28</lpage>.</citation>
</ref>
<ref id="bibr34-0192623312464309">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schatteman</surname>
<given-names>G. C.</given-names>
</name>
<name>
<surname>Awad</surname>
<given-names>O.</given-names>
</name>
</person-group> (<year>2004</year>). <article-title>Hemangioblasts, angioblasts, and adult endothelial cell progenitors</article-title>. <source>Anat Rec A Discov Mol Cell Evol Biol</source> <volume>276</volume>, <fpage>13</fpage>–<lpage>21</lpage>.</citation>
</ref>
<ref id="bibr36-0192623312464309">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Terada</surname>
<given-names>T.</given-names>
</name>
</person-group> (<year>2011</year>). <article-title>Angiosarcoma of the oral cavity</article-title>. <source>Head Neck Pathol</source> <volume>5</volume>, <fpage>67</fpage>–<lpage>70</lpage>.</citation>
</ref>
<ref id="bibr37-0192623312464309">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Urbich</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Dimmeler</surname>
<given-names>S.</given-names>
</name>
</person-group> (<year>2004</year>). <article-title>Endothelial progenitor cells: Characterization and role in vascular biology</article-title>. <source>Circ Res</source> <volume>95</volume>, <fpage>343</fpage>–<lpage>53</lpage>.</citation>
</ref>
<ref id="bibr38-0192623312464309">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>von Beust</surname>
<given-names>B. R.</given-names>
</name>
<name>
<surname>Suter</surname>
<given-names>M. M.</given-names>
</name>
<name>
<surname>Summers</surname>
<given-names>B.A.</given-names>
</name>
</person-group> (<year>1988</year>). <article-title>Factor VIII-related antigen in canine endothelial neoplasms: An immunohistochemical study</article-title>. <source>Vet Pathol</source> <volume>25</volume>, <fpage>251</fpage>–<lpage>55</lpage>.</citation>
</ref>
<ref id="bibr39-0192623312464309">
<citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname>Weiss</surname>
<given-names>S. W.</given-names>
</name>
<name>
<surname>Goldblum</surname>
<given-names>J. R.</given-names>
</name>
</person-group> (<year>2008</year>). <article-title>Malignant vascular tumors</article-title>. In <source>Enzinger and Weiss’s Soft Tissue Tumors</source>, <edition>5th ed</edition>. (<person-group person-group-type="editor">
<name>
<surname>Weis</surname>
<given-names>S. W.</given-names>
</name>
<name>
<surname>Goldblum</surname>
<given-names>J. R.</given-names>
</name>
</person-group>, eds.), pp <fpage>703</fpage>–<lpage>32</lpage>. <publisher-name>Mosley Elsevier</publisher-name>, <publisher-loc>China</publisher-loc>.</citation>
</ref>
<ref id="bibr40-0192623312464309">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yoder</surname>
<given-names>M. C.</given-names>
</name>
<name>
<surname>Mead</surname>
<given-names>L. E.</given-names>
</name>
<name>
<surname>Prater</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Krier</surname>
<given-names>T. R.</given-names>
</name>
<name>
<surname>Mroueh</surname>
<given-names>K. N.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Krasich</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Temm</surname>
<given-names>C. J.</given-names>
</name>
<name>
<surname>Prchal</surname>
<given-names>J. T.</given-names>
</name>
<name>
<surname>Ingram</surname>
<given-names>D. A.</given-names>
</name>
</person-group> (<year>2007</year>). <article-title>Redefining endothelial progenitor cells via clonal analysis and hematopoietic stem/progenitor cell principals</article-title>. <source>Blood</source> <volume>109</volume>, <fpage>1801</fpage>–<lpage>809</lpage>.</citation>
</ref>
<ref id="bibr41-0192623312464309">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yonemori</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Tsuta</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Ando</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Hirakawa</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Hatanaka</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Matsuno</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Chuman</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Yamazaki</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Fujiwara</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Hasegawa</surname>
<given-names>T.</given-names>
</name>
</person-group> (<year>2011</year>). <article-title>Contrasting prognostic implications of platelet-derived growth factor receptor-beta and vascular endothelial growth factor receptor-2 in patients with angiosarcoma</article-title>. <source>Ann Surg Oncol</source> <volume>18</volume>, <fpage>2841</fpage>–<lpage>50</lpage>.</citation>
</ref>
<ref id="bibr42-0192623312464309">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zietz</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Rossle</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Haas</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Sendelhofert</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Hirschmann</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Sturzl</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Lohrs</surname>
<given-names>U.</given-names>
</name>
</person-group> (<year>1998</year>). <article-title>MDM-2 oncoprotein overexpression, p53 gene mutation, and VEGF up-regulation in angiosarcomas</article-title>. <source>Am J Pathol</source> <volume>153</volume>, <fpage>1425</fpage>–<lpage>33</lpage>.</citation>
</ref>
<ref id="bibr43-0192623312464309">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zindy</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Nilsson</surname>
<given-names>L. M.</given-names>
</name>
<name>
<surname>Nguyen</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Meunier</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Smeyne</surname>
<given-names>R. J.</given-names>
</name>
<name>
<surname>Rehg</surname>
<given-names>J. E.</given-names>
</name>
<name>
<surname>Eberhart</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Sherr</surname>
<given-names>C. J.</given-names>
</name>
<name>
<surname>Roussel</surname>
<given-names>M. F.</given-names>
</name>
</person-group> (<year>2003</year>). <article-title>Hemangiosarcomas, medulloblastomas, and other tumors in Ink4c/p53-null mice</article-title>. <source>Cancer Res</source> <volume>63</volume>, <fpage>5420</fpage>–<lpage>27</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>